16-68813471-C-G

Position:

chr16-68813471-C-G

Variant summary

Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2

This summary comes from the ClinGen Evidence Repository: NM_004360.5(CDH1):c.1296C>G (p.Asn432Lys) variant has been observed in more than 10 (29) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; ClinVar SCVs: SCV000217409.6, SCV000545471.7, internal lab contributors). The CDH1-VCEP recommended a variant to reach a likely benign classification based on BS2 alone. In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA196286/MONDO:0100488/007

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)

Exomes 𝑓: 0.0000068 ( 0 hom. )

Consequence

CDH1
NM_004360.5 missense

Scores

Clinical Significance

Likely benign reviewed by expert panel P:2U:4B:2

Conservation

PhyloP100: -2.66

Variant links:

Genes affected

CDH1 (HGNC:1748): (cadherin 1) This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function of this gene is thought to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. This gene is present in a gene cluster with other members of the cadherin family on chromosome 16. [provided by RefSeq, Nov 2015]

CDH1 links:

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -4 ACMG points.

BS2

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE
CDH1	NM_004360.5 linkuse as main transcript	c.1296C>G	p.Asn432Lys	missense_variant	9/16	ENST00000261769.10
CDH1	NM_001317185.2 linkuse as main transcript	c.-320C>G		5_prime_UTR_variant	9/16
CDH1	NM_001317186.2 linkuse as main transcript	c.-524C>G		5_prime_UTR_variant	9/15
CDH1	NM_001317184.2 linkuse as main transcript	c.1137+1208C>G		intron_variant

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
CDH1	ENST00000261769.10 linkuse as main transcript	c.1296C>G	p.Asn432Lys	missense_variant	9/16	1	NM_004360.5	P1	P12830-1

Frequencies

GnomAD3 genomes

AF:

0.00000657

AC:

AN:

152168

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.00

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.000193

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.00

Gnomad OTH

AF:

0.00

GnomAD3 exomes

AF:

0.0000239

AC:

AN:

251484

Hom.:

AF XY:

0.0000147

AC XY:

AN XY:

135912

show subpopulations

Gnomad AFR exome

AF:

0.00

Gnomad AMR exome

AF:

0.00

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.000326

Gnomad SAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.00

Gnomad NFE exome

AF:

0.00

Gnomad OTH exome

AF:

0.00

GnomAD4 exome

AF:

0.00000684

AC:

AN:

1461860

Hom.:

Cov.:

AF XY:

0.00000688

AC XY:

AN XY:

727234

show subpopulations

Gnomad4 AFR exome

AF:

0.00

Gnomad4 AMR exome

AF:

0.00

Gnomad4 ASJ exome

AF:

0.00

Gnomad4 EAS exome

AF:

0.000202

Gnomad4 SAS exome

AF:

0.00

Gnomad4 FIN exome

AF:

0.00

Gnomad4 NFE exome

AF:

8.99e-7

Gnomad4 OTH exome

AF:

0.0000166

GnomAD4 genome

AF:

0.00000657

AC:

AN:

152168

Hom.:

Cov.:

AF XY:

0.0000135

AC XY:

AN XY:

74324

show subpopulations

Gnomad4 AFR

AF:

0.00

Gnomad4 AMR

AF:

0.00

Gnomad4 ASJ

AF:

0.00

Gnomad4 EAS

AF:

0.000193

Gnomad4 SAS

AF:

0.00

Gnomad4 FIN

AF:

0.00

Gnomad4 NFE

AF:

0.00

Gnomad4 OTH

AF:

0.00

Bravo

AF:

0.0000189

ExAC

AF:

0.0000247

AC:

ClinVar

Significance: Likely benign

Submissions summary: Pathogenic:2Uncertain:4Benign:2

Revision: reviewed by expert panel

LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome

Uncertain:2

Uncertain significance, criteria provided, single submitter	clinical testing	Ambry Genetics	Sep 19, 2023	The p.N432K variant (also known as c.1296C>G), located in coding exon 9 of the CDH1 gene, results from a C to G substitution at nucleotide position 1296. The asparagine at codon 432 is replaced by lysine, an amino acid with similar properties. This variant has been reported in a diffuse gastric cancer patient; RNA analysis of gastric tissue obtained from this patient revealed that the this variant could generate a shortened transcript lacking exon 9, which was predicted to result in an in-frame deletion of 183 amino acids in the extracellular domain (Li X et al. Fam. Cancer 2013 Sep; 12(3):547-54). However, this transcript was not detected in the normal tissue from this individual (Li X et al. Fam. Cancer 2013 Sep; 12(3):547-54). In addition, internal RNA studies have demonstrated that this alteration does not result in abnormal splicing in the set of samples tested (Ambry internal data). In a study of 99 Chinese breast cancer patients with family histories of cancer, this variant was observed in one patient with invasive ductal carcinoma diagnosed at age 47, who had a family history of two relatives with gastric cancer of unknown histology (Yang X et al. PLoS ONE 2015; 10(4):e0125571). This alteration was not observed in 7,051 unselected female breast cancer patients and was observed with an allele frequency of 0.00018 in 11,241 female controls of Japanese ancestry (Momozawa Y et al. Nat Commun. 2018 10;9:4083). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Uncertain significance, criteria provided, single submitter	clinical testing	Color Diagnostics, LLC DBA Color Health	Jul 15, 2021	This missense variant replaces asparagine with lysine at codon 432 of the CDH1 protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast and gastric cancer in the literature (PMID: 23435907, 25927356), but also in unaffected controls (PMID: 30287823). This variant has been identified in 6/251484 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

Neoplasm of stomach

Pathogenic:1

Likely pathogenic, no assertion criteria provided

clinical testing

3DMed Clinical Laboratory Inc

Dec 08, 2017

- -

Ovarian cancer

Pathogenic:1

Likely pathogenic, criteria provided, single submitter

clinical testing

Laboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan University

Jan 01, 2022

- -

not specified

Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Dec 23, 2019

Variant summary: CDH1 c.1296C>G (p.Asn432Lys) results in a non-conservative amino acid change located in the Cadherin-like domain (IPR002126) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. 4/5 computational tools predict no significant impact on normal splicing. However, one experimental study showed this variant generated the exon9-skipping (Li_2013). However, in the absence of experimental evidence evaluating an impact on protein function, this observation does not allow convincing conclusions about the variant effect. Furthermore, the ACMG guidelines for CDH1 variants recommend a supporting (not strong or moderate) weight for evidence that would result in in-frame transcripts such as deletion of exon 9 in CDH1. The variant allele was found at a frequency of 2.9e-05 in 274816 control chromosomes (gnomAD and publications). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1296C>G has been reported in the literature in individuals affected with breast cancer and gastric cancer as well as in two health controls (Li_2013, Yang_2015, Momozawa_2018). These reports do not provide unequivocal conclusions about association of the variant with Breast Cancer. Four ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (3x) and likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as uncertain significance. -

Familial cancer of breast

Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Baylor Genetics

Jan 16, 2024

- -

Hereditary diffuse gastric adenocarcinoma

Benign:1

Likely benign, criteria provided, single submitter

clinical testing

Invitae

Dec 08, 2023

- -

CDH1-related diffuse gastric and lobular breast cancer syndrome

Benign:1

Likely benign, reviewed by expert panel

curation

ClinGen CDH1 Variant Curation Expert Panel

Sep 25, 2023

NM_004360.5(CDH1):c.1296C>G (p.Asn432Lys) variant has been observed in more than 10 (29) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; ClinVar SCVs: SCV000217409.6, SCV000545471.7, internal lab contributors). The CDH1-VCEP recommended a variant to reach a likely benign classification based on BS2 alone. In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Pathogenic

0.80

BayesDel_addAF

Benign

-0.34

BayesDel_noAF

Benign

-0.42

CADD

Benign

5.1

DANN

Uncertain

0.98

DEOGEN2

Uncertain

0.54

D;T;T;.

Eigen

Benign

-0.68

Eigen_PC

Benign

-1.0

FATHMM_MKL

Benign

0.079

LIST_S2

Uncertain

0.89

D;D;D;D

M_CAP

Benign

0.082

MetaRNN

Pathogenic

0.86

D;D;D;D

MetaSVM

Benign

-0.29

MutationAssessor

Uncertain

2.6

M;.;.;.

MutationTaster

Benign

0.97

D;N

PrimateAI

Uncertain

0.51

PROVEAN

Pathogenic

-4.6

D;.;.;.

REVEL

Uncertain

0.33

Sift

Uncertain

0.0050

D;.;.;.

Sift4G

Uncertain

0.016

D;T;D;T

Polyphen

1.0

D;.;.;.

Vest4

0.76

MutPred

0.78

Gain of methylation at N432 (P = 0.0154);Gain of methylation at N432 (P = 0.0154);Gain of methylation at N432 (P = 0.0154);Gain of methylation at N432 (P = 0.0154);

MVP

0.67

MPC

0.97

ClinPred

0.77

GERP RS

-9.6

Varity_R

0.73

gMVP

0.77

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over